Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Low in Vitro Antifungal Activity of Tavaborole Against Yeasts and Moulds from Onychomycosis.

Abastabar M, Haghani I, Shokohi T, Hedayati MT, Aghili SR, Jedi A, Dadashi S, Shabanzadeh S, Hosseini T, Aslani N, Meis JF, Badali H.

Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01632-18. doi: 10.1128/AAC.01632-18. [Epub ahead of print]

PMID:
30224524
2.

The Current Status and Perspectives of Delivery Strategy for Boron-based Drugs.

Yinghuai Z, Lin X, Xie H, Li J, Hosmane NS, Zhang Y.

Curr Med Chem. 2018 Sep 3. doi: 10.2174/0929867325666180904105212. [Epub ahead of print]

PMID:
30182851
3.

Tavaborole.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

4.

Part II: Onychomycosis: Treatment and Prevention of Recurrence.

Lipner SR, Scher RK.

J Am Acad Dermatol. 2018 Jun 27. pii: S0190-9622(18)32187-X. doi: 10.1016/j.jaad.2018.05.1260. [Epub ahead of print] Review.

PMID:
29959962
5.

Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018).

Nocentini A, Supuran CT, Winum JY.

Expert Opin Ther Pat. 2018 Jun;28(6):493-504. doi: 10.1080/13543776.2018.1473379. Epub 2018 May 11. Review. Erratum in: Expert Opin Ther Pat. 2018 Jun;28(6):vii.

PMID:
29727210
6.

Common drug-drug interactions in antifungal treatments for superficial fungal infections.

Gupta AK, Versteeg SG, Shear NH.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):387-398. doi: 10.1080/17425255.2018.1461834. Epub 2018 Apr 26. Review.

PMID:
29633864
7.

Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis.

Markinson B, Ghannoum M, Winter T, Rycerz A, Rock F, Gupta AK.

J Am Podiatr Med Assoc. 2018 Jan;108(1):12-19. doi: 10.7547/16-154. Review.

PMID:
29547036
8.
9.

Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline Infection.

Pariser DM, Wendelken ME, Rycerz AM Jr, Gellings Lowe N, Yost JM, Lipner SR.

J Drugs Dermatol. 2018 Feb 1;17(2):168-172.

PMID:
29462224
10.
11.

In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails.

Gupta AK, Vlahovic TC, Foley KA, Lowe NG, Turner R, Brown M, Hall S.

J Dermatolog Treat. 2018 Sep;29(6):633-636. doi: 10.1080/09546634.2017.1422078. Epub 2018 Jan 10.

PMID:
29307243
12.

Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole

Pollak RA, Ilie C.

J Drugs Dermatol. 2017 Dec 1;16(12):1269-1273.

PMID:
29240863
13.

Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.

Rich P, Vlahovic TC, Joseph WS, Zane LT, Hall SB, Gellings Lowe N, Adigun CG.

Cutis. 2017 Oct;100(4):259-264.

PMID:
29136060
14.

In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.

Kubota-Ishida N, Takei-Masuda N, Kaneda K, Nagira Y, Chikada T, Nomoto M, Tabata Y, Takahata S, Maebashi K, Hui X, Maibach HI.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e00779-17. doi: 10.1128/AAC.00779-17. Print 2018 Jan.

15.

Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.

Aly R, Gupta AK, Winter T, Zane LT, Vlahovic T.

J Drugs Dermatol. 2017 Oct 1;16(10):1016-1021.

PMID:
29036255
16.

Utility of Boron in Dermatology.

Jackson DG, Cardwell LA, Oussedik E, Feldman SR.

J Dermatolog Treat. 2017 Aug 9:1-20. doi: 10.1080/09546634.2017.1363850. [Epub ahead of print]

PMID:
28789577
17.

Development and Validation of an HPLC-UV Method to Quantify Tavaborole During in Vitro Transungual Permeation Studies.

Tampucci S, Terreni E, Burgalassi S, Chetoni P, Monti D.

J AOAC Int. 2018 Mar 1;101(2):437-443. doi: 10.5740/jaoacint.17-0039. Epub 2017 Aug 1.

PMID:
28766480
18.

Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment.

Gupta AK, Versteeg SG, Shear NH.

J Cutan Med Surg. 2017 Nov/Dec;21(6):525-539. doi: 10.1177/1203475417716362. Epub 2017 Jun 22. Review.

PMID:
28639462
19.
20.

Topical Treatment for Onychomycosis: Is it More Effective than the Clinical Data Suggests?

Elewski BE, Vlahovic TC, Korotzer A.

J Clin Aesthet Dermatol. 2016 Nov;9(11):34-39. Epub 2016 Nov 1. Review.

Supplemental Content

Loading ...
Support Center